AmgenFRA:AMG +0.77%87 Dividend Yield % is 2.76% as of Jun. 26, 2026, which is 1% below its 10-year median of 2.78. GuruFocus rates FRA:AMG with a GF Score™ of 87/100 and a GF Value™ of €305.87 (Fairly Valued). The stock has 6 warning signs investors should review. Among 516 Drug Manufacturers companies, Amgen ranks better than 62.21% on this metric.
As of today (2026-06-26), the Trailing Annual Dividend Yield of Amgen is 2.76%.
The historical rank and industry rank for Amgen's Dividend Yield % or its related term are showing as below:
FRA:AMG'
s Dividend Yield % Range Over the Past 10 Years
Min: 2.05 Med: 2.78 Max: 3.72
Current: 2.76
During the past 13 years, the highest Dividend Yield of Amgen was 3.72%. The lowest was 2.05%. And the median was 2.78%.
FRA:AMG's Dividend Yield % is ranked better than 62.21% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.005
vs FRA:AMG: 2.76
During the past 12 months, Amgen's average Dividends Per Share Growth Rate was 5.80% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 7.10% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 8.40% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 11.10% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Amgen was 63.30% per year. The lowest was 7.10% per year. And the median was 12.40% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Amgen (FRA:AMG) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Amgen's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AMG vs GILD, PFE, BMY: Dividend Yield % Comparison
For the Drug Manufacturers - General subindustry, Amgen's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Amgen's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Amgen Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 2.520000
2026-05-15
2026-05-15
2026-06-05
Cash Dividend
quarterly
USD:EUR 0.856000
USD 2.520000
2026-02-13
2026-02-13
2026-03-06
Cash Dividend
quarterly
USD:EUR 0.846000
USD 2.380000
2025-11-21
2025-11-21
2025-12-12
Cash Dividend
quarterly
USD:EUR 0.865000
USD 2.380000
2025-08-22
2025-08-22
2025-09-12
Cash Dividend
quarterly
USD:EUR 0.859000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Amgen's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
8.39216
/
306.40
=
2.74 %
Current Share Price is €306.40. Amgen's Dividends per Share for the trailing twelve months (TTM) ended in Today is €8.39216.
Amgen's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
8.62848
/
306.40
=
2.82 %
Current Share Price is €306.40. Amgen's Dividends per Share for the forward twelve months is calculated as €2.15712 * 4 = €8.62848.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (FRA:AMG) has a Dividend Yield % of 2.76% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Amgen and its competitors. This is near median its historical median of 2.78. Over the past decade, Amgen's Dividend Yield % has ranged from 2.05 to 3.72. According to the industry distribution chart, Amgen ranks #195 out of 516 companies in the Drug Manufacturers industry, placing it in the top 37.8%.
Is Amgen's Dividend Yield % too high?
Amgen's current Dividend Yield % of 2.76% is near median its 10-year median of 2.78. Over the past 10 years, this metric has ranged from a low of 2.05 to a high of 3.72. The Drug Manufacturers industry median Dividend Yield % is 2.01. Amgen's value of 2.76% is 37.7% above this industry median. Based on the distribution chart, Amgen ranks #195 out of 516 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amgen has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Dividend Yield % compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #195 out of 516 companies for Dividend Yield %. This puts Amgen in the upper half of its industry. The industry median Dividend Yield % is 2.01. Amgen's value of 2.76% is 37.7% above this benchmark. Historically, Amgen's own Dividend Yield % has ranged from 2.05 to 3.72 over the past decade. While the company's 10-year median is 2.78 vs. the industry median of 2.01, Amgen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.01, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current Dividend Yield % of 2.76% is 37.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current Dividend Yield % is 2.76%, which is near median its own 10-year median of 2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (FRA:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €305.87, compared to a current price of €306.40 — trading 0.2% above its estimated fair value. The current Dividend Yield % is 2.76%, which is near median its 10-year median of 2.78 and 37.7% above the Drug Manufacturers industry median of 2.01. Amgen's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Amgen (FRA:AMG), the current Dividend Yield % is 2.76% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (FRA:AMG) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be overvalued.
The current stock price of €306.40 is trading 0.2% above its estimated GF Value™ of €305.87.
GuruFocus considers Amgen to be Fairly Valued.
Key valuation signals for FRA:AMG:
Dividend Yield %: 2.76% (near median its 10-year median of 2.78)
GF Value™: €305.87 vs. price of €306.40 (0.2% above fair value)
Industry Position: 37.7% above the Drug Manufacturers median (#195 of 516)
No single metric tells the full story. See the FRA:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
87GF Score
Get the complete analysis for FRA:AMG
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AMG has been successfully added to your 
